Press Release Archive
(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced, at the request of the U.S. Food and Drug Administration (FDA), the suspension of the chronic low back pain and painful diabetic peripheral neuropathy studies in the clinical program for the investigational compound tanezumab. Investigation of the compound continues in some areas of high unmet medical need, including cancer pain. The FDA’s request follows further consideration
July 13, 2010 - Pfizer And SMC Collaborate On Liver Cancer
(BUSINESS WIRE)--Samsung Medical Center and the world’s leading bio-pharmaceutical company Pfizer Inc. announced that they have formed a research partnership to jointly analyze tumors from Korean patients to generate gene expression profiles and that may ultimately direct therapies and enhance clinical outcomes in the patients with liver cancer. The two organizations held a signing ceremony at the main conference hall located on the
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE), together with its collaborator on the Alzheimer’s Immunotherapy Program, Janssen Alzheimer Immunotherapy, presented new research this week at the Alzheimer’s Association International Conference on Alzheimer's Disease 2010 (ICAD 2010) from two podium and four poster presentations. This research indicates there may be potential for an increased risk of comorbid conditions, such as seizures,
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present new data on its investigational compounds targeting various aspects of Alzheimer’s disease (AD), a complex degenerative brain disorder. New findings on the role of comorbidities, the burden of care and costs associated with AD, also will be discussed. These data, some in collaboration with our partners, will be presented at the Alzheimer's Association International Conference on
(BUSINESS WIRE)--Pfizer Inc. today announced a $100 million (U.S.) investment into the expansion of its Singapore Nutrition Plant, helping it continue to set the standard for the manufacture of high-quality, safe and environmentally sustainable nutritional products for infants and children. This expansion, which brings the total investment in the plant to $372 million (U.S.), makes it one of the largest nutritional plants worldwide
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced it has received European Commission approval of a new chewable form of Lipitor (atorvastatin calcium) suitable for use in children aged 10 or older with high levels of LDL (“bad”) cholesterol and high triglycerides due to the inherited disorder familial hypercholesterolemia and other primary causes, which can increase the risk of heart disease and premature death. This pediatric indication
(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 3, 2010. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2010 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web
June 23, 2010 - Pfizer Declares An 18-Cent Third-Quarter 2010 Dividend
(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared an 18-cent third-quarter 2010 dividend on the company’s common stock, payable September 1, 2010, to shareholders of record at the close of business on August 6, 2010. The third-quarter 2010 cash dividend will be the 287th consecutive quarterly dividend paid by Pfizer.
June 22, 2010 - Pfizer Suspends Tanezumab Osteoarthritis Clinical Trial Program
(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the suspension of the osteoarthritis clinical program for the investigational compound tanezumab following a request by the U.S. Food and Drug Administration (FDA). The worldwide suspension – which is effective immediately – follows a small number of reports of tanezumab patients experiencing the worsening of osteoarthritis leading to joint replacement. To date, this adverse event has
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Ergonex Pharma GmbH announced today that they have entered into an agreement under which Pfizer will acquire terguride, which is in development as a potential treatment for Pulmonary Arterial Hypertension (PAH). Under the terms of the agreement, Pfizer will support the completion of the ongoing Phase 2 trial for terguride and will have exclusive worldwide rights excluding Japan to commercialize
(BUSINESS WIRE)--Caduet® (amlodipine besylate/atorvastatin calcium) was associated with a significantly reduced calculated 10-year risk of coronary heart disease (CHD) based on a Framingham risk assessment model. In addition, Caduet was shown to reduce calculated fatal cardiovascular disease (CVD) risk, as a secondary trial endpoint based on the SCORE risk assessment model. The Framingham and SCORE risk assessment models are widely used in the
(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced that new data, published today by The Lancet, show that arthritis patients at increased gastrointestinal (GI) risk taking CELEBREX demonstrated a significantly lower incidence of the novel composite endpoint of clinically significant upper and lower GI events compared with patients taking diclofenac plus omeprazole. This difference was driven by clinically significant decreases in hemoglobin
(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Geno Germano, President and General Manager, Specialty Care & Vaccines, at the Goldman Sachs 31st Annual Global Healthcare Conference on Tuesday, June 15, 2010 at 8:35 a.m. Pacific Daylight Saving Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Goldman Sachs
(BUSINESS WIRE)--Results from a Phase 3 study demonstrate MACUGEN® (pegaptanib sodium) significantly improved vision in patients with diabetic macular edema (DME), a complication of diabetes that is a leading cause of blindness in people of working age.(1) In the study, 37 percent of patients treated with MACUGEN gained two lines, or 10 letters, of vision on the ETDRS eye chart at 54 weeks, compared to 20 percent of patients who received a
(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Epocrates, Inc., today announced a collaboration to give healthcare providers (HCPs) mobile access to the Pfizer Medical Information Group to obtain scientific answers to their product questions or to report an adverse event. For the first time, clinicians can make direct contact through the Epocrates drug reference app on their iPhone® device to pharmaceutical manufacturers and immediately apply
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial’s independent Executive Steering Committee (ESC). The recommendations follow a second interim analysis by the independent Data Safety Monitoring Committee (DSMC) of the EMPHASIS-HF trial confirming the study has reached its primary efficacy endpoint early according to the protocol pre-defined
(BUSINESS WIRE)--Today, Pfizer Inc. named Mikael Dolsten, M.D., PhD, President of Pfizer Worldwide Research and Development, as the Company completes its integration of these functions following the Wyeth acquisition. Dr. Dolsten previously led Wyeth’s Research and Development organization from May 2008, and after the close of the Wyeth acquisition was named President of Pfizer’s BioTherapeutics Research & Development. Prior to his
(BUSINESS WIRE)--Pfizer Animal Health today announced its acquisition of Microtek International, Inc., a recognized innovator in aquaculture vaccines, R&D and healthcare diagnostic services. The acquisition further expands Pfizer’s commitment to a safe food supply from healthy beef and dairy cattle, swine, poultry and, now, fish. Total global fish production – largely for human consumption – now exceeds that of pork, poultry,
(BUSINESS WIRE)--Pfizer Oncology will present new data highlighting the company’s focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology (ASCO) meeting in Chicago from June 4-8. “Pfizer Oncology is committed to applying discoveries from cancer biology and genetics to the development of new
(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Jean-Michel Halfon, President and General Manager, Emerging Markets, at the Citi 2010 Global Healthcare Conference on Wednesday, May 26, 2010, at 10:30 a.m. Eastern Daylight Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Citi 2010 Global HealthcarConference” link
Pages
Press release archive foot note
Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.
Stay on top of Pfizer breaking news: Get News Alerts by RSS. 
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
 |
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page. |
Current Stock Price
| . |
. . |
| %Change | . | 52 Wk. High | . |
| Day High | . | 52 Wk. Low | . |
| Day Low | . | Mkt. Cap(Bil) | . |
| Open | . | ||
| Prev Close | . | Symbol | . |
| Vol. | . | Exchange | . |
Online Pfizer Press Kit
Our press kit provides information that might help you write stories or simply find out more about Pfizer.